Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 501–600 of 1,004
Shah, T., Engmann, J., Dale, C. E., Shah, S. H., White, J., Giambartolomei, C., McLachlan, S., Zabaneh, D., Cavadino, A., Finan, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071345 · Cited by 42
“Moreover, variants have been identified for their associations with many other cardiovascular disease (CVD)-associated biomarkers of less certain causal relevance, including HDL-cholesterol and triglycerides [6], apolipoproteins [9], lipoprotein (a) [10], inflammation and coagulation factors [11], uric acid, and gluco…”
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 40
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 43
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 40
“Because small apo(a) isoforms can be made in higher particle numbers per unit time than large isoforms 113) , the size of the apo(a) isoform determined by the number of Kringle 4 type 2 repeats is inversely correlated to plasma Lp(a) levels 114, 115) .”
BackgroundMethodLin, J. J., Reilly, M. P., Terembula, K., & Wilson, F. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114397 · Cited by 40
“Prior Mendelian randomization studies established causality between CV disease and genetic variations in the LPA gene [31, 37].”
BackgroundGenetic risks and childhood-onset asthma
Cookson, W., Moffatt, M. F., & Strachan, D. P. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.026 · Cited by 43
Latest developments in the treatment of lipoprotein (a)
Bos, S., Yayha, R., & van Lennep, J. E. R. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000126 · Cited by 39
Toth, P. P., Jones, S. R., Monsalvo, M. L., Elliott‐Davey, M., López, J. A. G., & Banach, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014129 · Cited by 37
“and Mendelian randomization studies confirm that elevated levels of Lp(a) are causally associated with risk for ASCVDrelated events.(1,5,6,21,22) Neither statins nor ezetimibe impact serum levels of Lp(a).”
BackgroundLoh, W. J., Chang, X., Aw, T. C., Phua, S. K., Low, A. F.-H., Chan, M. Y., Watts, G. F., & Heng, C. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.018 · Cited by 38
Tindale, L. C., Leach, S., Spinelli, J. J., & Brooks-Wilson, A. R. (2017) · Oncotarget · doi:10.18632/oncotarget.15296 · Cited by 36
“, 2009 [22] LPA(3) rs10455872 Deleterious Risk for coronary disease Clarke et al.”
BackgroundMethodInfluentialLipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 40
“Interestingly, rs10455872 and rs3798220 variants have been further suggested to correlate with the increased risk of coronary heart disease (CHD) [37].”
BackgroundThe functions of apolipoproteins and lipoproteins in health and disease
Ma, Z., Zhong, J., Tu, W., Li, S., & Chen, J. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00218-7 · Cited by 41
“…plasma Lp(a) concentrations and CHD. Robert Clarke et al. confirmed in the large multicenter PRO-CARDIS study that differences in LPA are substantially associated with elevated levels of Lp(a) and an increased risk of CHD, supporting the idea that Lp(a) is key to coronary artery disease [56].”
BackgroundKatsi, V. K., Argyriou, N., Fragoulis, C., & Tsioufis, K. P. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12070256 · Cited by 39
“Importantly, Lp(a) is largely resistant to most lifestyle modifications and medications that effectively lower LDL cholesterol, such as statins, and its levels typically remain stable throughout a person’s lifetime due to strong genetic influence [21].”
Cai, D.-P., He, Y., Yang, X., Zhao, X., & Xu, H. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.009 · Cited by 36
Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia
Gelsinger, C., Steinhagen‐Thiessen, E., & Kassner, U. (2012) · Drugs · doi:10.2165/11635060-000000000-00000 · Cited by 38
“Patients with extensive Lp(a) levels are at high risk for CVD.[2,26-28] Former studies have shown that Lp(a) levels are elevated 3-fold in HeFH patients.”
BackgroundInfluentialThe genetics of coronary artery disease
Roberts, R., & Stewart, A. F. R. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283515b4b · Cited by 39
Kunutsor, S. K., Khan, H. M., Nyyssönen, K., & Laukkanen, J. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.069 · Cited by 36
“Lipoprotein (a) [Lp(a)], a liver derived lipoprotein composed of a central core with apolipoprotein B100 (apo B100) covalently bound to apolipoprotein (a) [apo(a)],[1] is an established and independent risk factor for myocardial infarction (MI), coronary heart disease (CHD),stroke, heart failure, and calcific aortic s…”
BackgroundLipoprotein Disorders and Cardiovascular Disease
Genest, J. J., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00047-0 · Cited by 38
Plasma cytokines and risk of coronary heart disease in the PROCARDIS study
Clarke, R., Valdés‐Márquez, E., Hill, M., Gordon, J., Farrall, M., Hamsten, A., Watkins, H. C., & Hopewell, J. C. (2018) · Open Heart · doi:10.1136/openhrt-2018-000807 · Cited by 38
“MetHOds study population CHD cases were recruited from four European countries (UK, Italy, Sweden and Germany) between 2004 and 2008 into a retrospective case–control study of CHD.(14) Cases had been previously diagnosed with CHD and also had a sibling who had been diagnosed with CHD before the age of 66 years.”
Self-citationDai, W., Long, J., Cheng, Y., Chen, Y., & Zhao, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-25835-5 · Cited by 36
Guertin, J., Kaiser, Y., Manikpurage, H. D., Perrot, N., Bourgeois, R., Couture, C., Wareham, N. J., Bossé, Y., Pîbarot, P., Stroes, E. S. G., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003271 · Cited by 37
The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta‐analysis
Jamialahmadi, T., Reiner, Ž., Alidadi, M., Kroh, M., Almahmeed, W. A., Ruscica, M., Sirtori, C. R., Rizzo, M., Santos, R. D., & Sahebkar, A. (2022) · BioMed Research International · doi:10.1155/2022/8435133 · Cited by 37
“We were also not able to establish the contribution of either apo (a) isoform size or variants in LPA gene [82].”
Legg-Calvé-Perthes Disease and Risks for Cardiovascular Diseases and Blood Diseases
Hailer, Y. D., Montgomery, S., Ekbom, A., Nilsson, O., & Bahmanyar, S. (2010) · PEDIATRICS · doi:10.1542/peds.2009-2935 · Cited by 36
Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism
Sticchi, E., Magi, A., Kamstrup, P. R., Marcucci, R., Prisco, D., Martinelli, I., Mannucci, P. M., Abbate, R., & Giusti, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149427 · Cited by 36
“02 [20] exon 36 (cds) C__25930271_10 Yes [20]”
BackgroundResultInfluentialRecent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 42
Yu, M., Wang, M.-L., Wang, J., Lin, B.-L., Zhao, X., Tao, X. W., Chen, Y., Li, P.-Y., Zhang, J., Ge, J.-B., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.367 · Cited by 35
Rudolf, J. W., & Lewandrowski, K. B. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.11.003 · Cited by 35
“92.(48) As mentioned previously, although LP(a) levels are an increasingly important part of cardiovascular risk prediction, the current lack of effective LP(a)-directed therapy tempers the value of routine testing at a functional or genetic level.”
The re-emergence of lipoprotein(a) in a broader clinical arena
Tsimikas, S. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.005 · Cited by 38
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
Waldmann, E., & Parhofer, K. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.016 · Cited by 35
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease
Gencer, B., & Mach, F. (2020) · Drugs · doi:10.1007/s40265-019-01243-5 · Cited by 36
Lipoprotein (a): Recent Updates on a Unique Lipoprotein
Saeed, A., Kinoush, S., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00940-5 · Cited by 35
Colantonio, L. D., Bittner, V., Safford, M. M., Marcovina, S. M., Brown, T. M., Jackson, E. A., Li, M., López, J. A. G., Monda, K. L., Plante, T. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025397 · Cited by 36
Maierean, S. M., Webb, R. J., Banach, M., & Mazidi, M. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac039 · Cited by 37
Association of endometriosis with cardiovascular disease: Genetic aspects (Review)
Vazgiourakis, V., Zervou, M. I., Papageorgiou, L., Chaniotis, D. I., Spandidos, D. A., Vlachakis, D. P., Eliopoulos, E., & Goulielmos, G. N. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5232 · Cited by 37
“Together with the lipoprotein(a) ( LPA ) locus, they exert the most prominent effect on the risk of devel‑ oping CAD (30).”
Concordance of a High Lipoprotein(a) Concentration Among Relatives
Reeskamp, L. F., Tromp, T. R., Patel, A. P., Ibrahim, S., Trinder, M., Haidermota, S., Hovingh, G. K., Stroes, E. S. G., Natarajan, P., & Khera, A. V. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3548 · Cited by 35
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science
Scipione, C. A., Koschinsky, M. L., & Boffa, M. B. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1415866 · Cited by 36
“A recent large-scale genetic study assessed the phenotypic impact of geneticallylowered Lp(a) levels from a combination of GWAS data, genome sequencing data from CHD patients and controls, and individual level data from over 100,000 patients.”
BackgroundInfluentialLarge-Scale Candidate Gene Analysis of HDL Particle Features
Kaess, B. M., Tomaszewski, M., Braund, P. S., Stark, K. J., Rafelt, S. E., Fischer, M., Hardwick, R. J., Nelson, C. P., Dębiec, R., Huber, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014529 · Cited by 35
“Genotypes in WGHS were imputed from GWA data based on the HumanHap300 Duo "+" chips or a combination of the HumanHuman300 Duo and iSelect chips (Illumina, San Diego, CA) with the Infinium II protocol [20].”
BackgroundMethodInfluentialSelf-citationLangsted, A., & Nordestgaard, B. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000681 · Cited by 35
Widen, E., Raben, T. G., Lello, L., & Hsu, S. D. H. (2021) · Genes · doi:10.3390/genes12070991 · Cited by 32
Youssef, A., Clark, J. R., Marcovina, S. M., Boffa, M. B., & Koschinsky, M. L. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317335 · Cited by 38
The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target
Koschinsky, M. L., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.017 · Cited by 35
Zhu, L., Fang, Y., Gao, B., Jin, X., Zheng, J., He, Y., & Huang, J. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02932-y · Cited by 37
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Genome-Wide Association Studies in Atherosclerosis
Sivapalaratnam, S., Motazacker, M. M., Maiwald, S., Hovingh, G. K., Kastelein, J. J. P., Levi, M. M., Trip, M. D., & Dallinga‐Thie, G. M. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0173-4 · Cited by 42
“A recent meta-analysis revealed that plasma Lp(a) concentration is a stronger biomarker for risk than the gene score based on above-mentioned SNPs [45].”
BackgroundZhigen, L., Li, G., Zhou, Y., Chen, Z., Yang, J.-Q., Zhang, Y., Sun, S., & Zhong, S. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-127 · Cited by 34
“Notably, certain genetic LPA variants, such as SNPs rs3798220 and rs10455872, are strongly associated with both increased Lp(a) levels and CAD risk in Caucasians [17].”
InfluentialZhao, J., Feng, Q., Wu, P., Warner, J. L., Denny, J. C., & Wei, W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212112 · Cited by 37
“Approximately 70% of Lp(a) variation can be attributed to variants at the LPA locus [20–22], and rs10455872 alone explains ~25% variation in circulating Lp(a) levels [16].”
BackgroundInfluentialMoriarty, P. M., & Hemphill, L. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.002 · Cited by 34
“However, the latest data reveal an increased atherogenicity and risk of CVD associated with Lp(a) regardless of LDL-C levels.(42,43) In 2010 the German government approved LA treatments for patients with ongoing CAD and Lp(a) levels greater than 60 mg/dL (Normal<30 mg/dL), irrespective of LDL-C levels.”
BackgroundMoving Targets: Recent Advances in Lipid-Lowering Therapies
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 39
Shah, N. P., Mulder, H. S., Lydon, E. J., Chiswell, K., Hu, X., Lampron, Z. M., Cohen, L., Patel, M. R., Taubes, S., Song, W., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035610 · Cited by 33
“10,11 Third, knowing a lipoprotein (a) level can help determine how aggressive patients and clinicians need to be in optimizing modifiable cardiovascular risk factors in addition to LDL-C, such as diabetes, hypertension, and obesity.”
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 34
Kral, B. G., Kalyani, R. R., Yanek, L. R., Vaidya, D. M., Fishman, E. K., Becker, D. M., & Becker, L. C. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.020 · Cited by 33
Genetics of frailty: A longevity perspective
Sathyan, S., & Verghese, J. (2020) · Translational research · doi:10.1016/j.trsl.2020.03.005 · Cited by 35
Mahmood, T. A., Minnier, J., Ito, M. K., Li, Q. H., Koren, A., Kam, I. W., Fazio, S., & Shapiro, M. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320915803 · Cited by 33
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 34
“Elevated plasma levels of Lp(a) are largely genetically determined and are associated with CVD risk [7,72] and aortic valve calcification [73,74].”
BackgroundZanetti, D., Gustafsson, S., Assimes, T. L., & Ingelsson, E. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.002996 · Cited by 35
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Habeeb, N. W.-A., Higgins, V., Venner, A. A., Bailey, D., Beriault, D. R., Collier, C. P., & Adeli, K. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.03.019 · Cited by 36
de Boer, L. M., Hutten, B. A., Zwinderman, A. H., & Wiegman, A. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac660 · Cited by 33
Valdés‐Márquez, E., Clarke, R., Hill, M., Watkins, H. C., & Hopewell, J. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad020 · Cited by 33
Self-citationThe Oxidized Lipoproteins In Vivo: Its Diversity and Behavior in the Human Circulation
Itabe, H., & Obama, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065747 · Cited by 34
“Increased sdLDL levels have been observed in patients with diabetes mellitus and coronary heart disease (CHD), and it is potentially a clinical marker for these diseased conditions [27,28].”
BackgroundInfluentialLipoprotein (a), LPA Ile4399Met, and Fibrin Clot Properties
Rowland, C. M., Pullinger, C. R., Luke, M. M., Shiffman, D., Green, L., Movsesyan, I., Devlin, J. J., Malloy, M. J., Kane, J. P., & Undas, A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.024 · Cited by 33
“However, it is unlikely that rs10455872 could explain the associations of rs3798220 with the clot properties in Caucasians because these two SNPs were independently associated with Lp(a) levels and CHD risk [26] and were on separate linkage disequilibrium blocks in Caucasians [34].”
BackgroundResultInfluentialVirani, S. S. (2017) · Frontiers in bioscience · doi:10.2741/4635 · Cited by 38
“Another era of heightened interest in Lp(a) followed in 2009, when robust evidence from Mendelian randomization studies6 and large cohort studies showed the association of Lp(a) with cardiovascular disease (CVD) events (7,8).”
BackgroundClarke, R., Wright, N., Lin, K., Yu, C., Walters, R. G., Lv, J., Hill, M., Kartsonaki, C., Millwood, I. Y., Bennett, D., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072086 · Cited by 32
“As in European individuals, 4,5 the associations of the 29 Lp(a)-associated SNPs with apo(a) isoforms identified in CKB showed that SNPs with the greatest effects on Lp(a) were associated with the smallest apo(a) isoforms.”
Self-citationGene silencing approaches for the management of dyslipidaemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.010 · Cited by 32
Dallmeier, D., & Köenig, W. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.01.003 · Cited by 39
Pro(a)LiFe-Study Group, Klingel, R., Heibges, A., & Fassbender, C. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0082-3 · Cited by 32
“2 Frequency of the small ( 22 KIV domain copies) apo(a) allele genotype, or high risk allele variants tagged by SNPs rs41055872 or rs3798220 [13], and corresponding mean Lp(a) concentrations (modified from [1])”
BackgroundLipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 35
Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events
Guédon, A. F., de Fréminville, J.-B., Mirault, T., Mohamedi, N., Rance, B., Fournier, N., Paul, J., Messas, E., & Goudot, G. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45720 · Cited by 33
Blood HER2 and Uromodulin as Causal Mediators of CKD
Sjaarda, J., Gerstein, H. C., Yusuf, S., Treleaven, D. J., Walsh, M. W., Mann, J. F. E., Hess, S., & Paré, G. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017070812 · Cited by 34
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 35
Cox, A. J., Hsu, F., Ng, M. C. Y., Langefeld, C. D., Freedman, B. I., Carr, J. J., & Bowden, D. W. (2014) · Diabetes Care · doi:10.2337/dc13-1514 · Cited by 35
Beaney, K. E., Cooper, J. A., Shahid, S. U., Ahmed, W., Qamar, R., Drenos, F., Crockard, M. A., & Humphries, S. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130754 · Cited by 33
“92 Clarke, Peden [40] LPA* rs10455872 Intergenic G 1.”
Emerging Risk Factors for Stroke: What Have We Learned From Mendelian Randomization Studies?
Hopewell, J. C., & Clarke, R. (2016) · Stroke · doi:10.1161/strokeaha.115.010646 · Cited by 36
“These studies suggest some common, but many distinct underlying mechanisms in the pathogenesis of IS subtypes and CHD.”
BackgroundInfluentialSelf-citationLiu, Y., Ma, H., Zhu, Q., Zhang, B., Yan, H., Li, H., Meng, J., Lai, W., Li, L., Yu, D., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p091009 · Cited by 32
“Large-scale genomewide association studies (GWASs) (10, 11) and candidate gene studies (12) have identified sets of SNPs that are significantly associated with serum Lp(a) concentration.”
BackgroundProprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
Guo, S., Xia, X.-D., Gu, H.-M., & Zhang, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_9 · Cited by 36
Should Lipoprotein(a) be Measured in Youth?
Kohn, B., Ashraf, A. P., & Wilson, D. P. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.08.042 · Cited by 31
Jun, J. E., Kang, H., Hwang, Y., Ahn, K. J., Chung, H.-Y., & Jeong, I. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108622 · Cited by 31
Wilson, D. P., Koschinsky, M. L., & Moriarty, P. M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000624 · Cited by 33
Murdock, D. R., Venner, E., Muzny, D. M., Metcalf, G., Murugan, M., Hadley, T. D., Chander, V., de Vries, P. S., Jia, X., Hussain, A., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01294-8 · Cited by 31
Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
Handhle, A., Viljoen, A., & Wierzbicki, A. S. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266244 · Cited by 33
Zhu, L., Zheng, J., Gao, B., Jin, X., He, Y., Zhou, L., & Huang, J. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02618-5 · Cited by 31
“Prior research has confirmed that Lp(a) elevations are independently associated with the risk of CAD [4, 18].”
BackgroundLoh, W. J., Chan, D. C., Mata, P., & Watts, G. F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.905941 · Cited by 32
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia
Olmastroni, E., Gazzotti, M., Averna, M. R., Arca, M., Tarugi, P., Calandra, S., Bertolini, S., Catapano, A. L., Casula, M., Arca, M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029223 · Cited by 31
Mendelian randomisation, lipids, and cardiovascular disease
Harrison, S. C., Holmes, M. V., & Humphries, S. E. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60481-4 · Cited by 31
Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease
Shu, L., Blencowe, M., & Yang, X. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00056 · Cited by 35
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
“Lp(a) is an established risk factor for cardiovascular disease [65,66], which consists of an LDL particle in which”
BackgroundClot or Not? Reviewing the Reciprocal Regulation Between Lipids and Blood Clotting
Zhang, Z., Rodriguez, M., & Zheng, Z. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.318286 · Cited by 31
Lipoprotein(a) and panvascular disease
Xu, R., Wang, Z., Dong, J., Yu, M., & Zhou, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02600-y · Cited by 31
“Among ASCVD outcomes, the link between Lp(a) and coronary heart disease (CHD) is the most well-established [22, 23, 59, 63, 64].”
Pelacarsen: Mechanism of action and Lp(a)-lowering effect
Bhatia, H. S., Bajaj, A., Goonewardena, S. N., & Moriarty, P. M. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.004 · Cited by 43
Sex hormones and lipoprotein(a) concentration
Gaeta, G. B., Lanero, S., Barra, S., Silvestri, N., Cuomo, V., Materazzi, C., & Vitagliano, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.548804 · Cited by 35
“Observational/preclinical and randomized clinical trials yielded conflicting results about the potential benefits of systemic HT in reducing the risk of CAD.”
BackgroundInfluentialLipoprotein(a): new insights from modern genomics
Afshar, M. S., & Thanassoulis, G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000392 · Cited by 30
Enkhmaa, B., Anuurad, E., Zhang, W., Yue, K., Li, C.-S., & Berglund, L. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078212 · Cited by 30
“8; 308; 69) Apo(a) expression n = 39 n = 116 n = 25 n = 55 n = 14 n = 61 Single isoform, n (%) 14 (36) 37 (32) 12 (48) 19 (35) 2 (14) 18 (30) Double isoforms, n (%) 25 (64) 78 (67) 13 (52) 35 (64) 12 (86) 43 (70) No isoform, n (%) 0 (0) 1 (1) 0 (0) 1 (2) 0 (0) 0 (0) Apo(a) dominance n = 25 n = 78 n = 13 n = 35 n = 12…”
Pathobiology of Lp(a) in calcific aortic valve disease
Mathieu, P., Arsenault, B. J., Boulanger, M., Bossé, Y., & Koschinsky, M. L. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1367286 · Cited by 33
Lyu, J., Li, Z., Wei, H., Liu, D., Chi, X., Gong, D., & Zhao, Q. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01484-x · Cited by 30
Lipoprotein (a) and Hypertension
Ward, N. C., Nolde, J. M., Chan, J., Carnagarin, R., Watts, G. F., & Schlaich, M. P. (2021) · Current Hypertension Reports · doi:10.1007/s11906-021-01161-6 · Cited by 35
Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj, A., & Cuchel, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17065 · Cited by 31
Silverio, A., Cancro, F. P., Esposito, L., Bellino, M., D’Elia, D., Verdoia, M., Vassallo, M. G., Ciccarelli, M., Vecchione, C., Galasso, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062161 · Cited by 32
Shiyovich, A., Berman, A. N., Besser, S. A., Biery, D. W., Kaur, G., Divakaran, S., Singh, A., Huck, D. M., Weber, B., Plutzky, J., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034493 · Cited by 31
“20,49,50 53 Although some of these studies have accounted for baseline characteristics and standard risk factors, the risk associated with elevated Lp(a) in relation to other risk factors has not been fully explored, and prior studies have not focused on modifiable risk factors.”
BackgroundFunctional primate genomics—leveraging the medical potential
Enard, W. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0901-4 · Cited by 30
“Genetic variants in LPA that increase Lp(a) levels increase the risk of coronary disease in humans [36].”
BackgroundLipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome
Jubran, A., Zetser, A., & Zafrir, B. (2019) · Cardiology Journal · doi:10.5603/cj.a2018.0106 · Cited by 32
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.